Research and Development of Generic Formulations (ΤΑCL1-0498641)

Genepharm, with a long-standing presence in the field of conventional pharmaceutical manufacturing, is implementing a significant project aimed both at upgrading our production capabilities and at enhancing our research and analytical infrastructure.

Within the framework of this project, we are modernizing our production lines for tablets, capsules, and other finished dosage forms of conventional medicines, ensuring higher efficiency, quality, and compliance with international standards. At the same time, we are making substantial investments to strengthen our research capabilities through the upgrade of laboratory facilities, analytical equipment, and evaluation processes for conventional active pharmaceutical ingredients.

The improvement of our research infrastructure enhances the company’s ability to conduct specialized analyses, to assess more accurately the quality of raw materials and finished products, and to develop new formulations of conventional medicines with increased stability and effectiveness. Through this investment, our company reinforces its position as a modern Greek pharmaceutical manufacturer, with a strong production and research base that supports domestic pharmaceutical self-sufficiency.

The main objective of the project is to develop and distribute these specific preparations on the Greek, European, and international markets.

The project is implemented within the framework of the National Recovery and Resilience Plan “Greece 2.0”, funded by the European Union – NextGenerationEU.